



Universiteit  
Leiden  
The Netherlands

## **Systems pharmacology and blood-brain barrier functionality in Parkinson's disease**

Ravenstijn, P.G.M.

### **Citation**

Ravenstijn, P. G. M. (2009, December 16). *Systems pharmacology and blood-brain barrier functionality in Parkinson's disease*. Retrieved from <https://hdl.handle.net/1887/14514>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14514>

**Note:** To cite this publication please use the final published version (if applicable).

**Systems Pharmacology and  
Blood-Brain Barrier Functionality  
in Parkinson's Disease**



# **Systems Pharmacology and Blood-Brain Barrier Functionality in Parkinson's Disease**

**Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit van Leiden,  
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 16 december 2009  
klokke 10.00 uur

door

**Paulien Gerarda Maria Ravenstijn**  
geboren te Terneuzen  
in 1977

## **Promotiecommissie**

Promotor : Prof. dr. M. Danhof

Co-promotor : Dr. E.C.M. de Lange

Overige Leden : Prof. dr. Y. Michotte

Prof. dr. J.J. van Hilten

Prof. dr. J. Bouwstra

Prof. dr. T. Hankemeier

Prof. dr. M.S. Oitzl

The research described in this thesis was sponsored by Lilly and conducted at the Division of Pharmacology of the Leiden/Amsterdam Center for Drug Research, Leiden University, the Neurodegeneration Drug Hunting Team of Eli Lilly & Co Ltd. in Windlesham, United Kingdom and the Department of Drug Disposition of Lilly Development Centre S.A. in Mont-Saint-Guibert, Belgium.

The only true wisdom is in knowing you know nothing  
*Socrates (470 B.C. - 399 B.C.)*

**The printing of this thesis was financially supported by:**

Leiden/ Amsterdam Center for Drug Research, Leiden, The Netherlands

Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium

Aurora Borealis Control BV, Schoonebeek, The Netherlands

ISBN 978-90-8570-424-9

Printed by : Wöhrmann Print Service

© Paulien Ravenstijn

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission from the author.

<b>Section I</b>	<b>General Introduction</b>	9
<b>Chapter 1</b>	<b>Scope and Outline of the Investigations</b>	11
<b>Chapter 2</b>	<b>Understanding Drug Response in Parkinson's Disease - the Role of the Blood-Brain Barrier</b>	19
	1. Introduction	20
	2. Parkinson's disease	21
	3. Current drug treatments for Parkinson's disease	29
	4. Mechanisms involved in target site distribution of CNS drugs	34
	5. Sources of variation in mechanisms contributing to the response profile	46
	6. The BBB in neurodegeneration: implications for PK-PD relationships of antiparkinson drugs	56
	7. Summary and concluding remarks	59
	8. References	60
<b>Chapter 3</b>	<b>Animal Models as a Tool in Systems Pharmacology Research on Parkinson's Disease</b>	91
	1. Introduction	92
	2. Animal models of Parkinson's disease	95
	3. Measuring target site distribution and BBB functionality in animal models of Parkinson's disease	107
	4. Measuring behaviour and drug effects in animal models of Parkinson's disease	109
	5. Mechanism-based PK-PD modelling techniques	112
	6. Conclusions	115
	7. References	118



<b>Section II</b>	<b>The Rotenone Rat Model of Parkinson's Disease</b>	137
<b>Chapter 4</b>	<b>The Exploration of Rotenone as a Toxin for Inducing Parkinson's Disease in Rats - Application in BBB Transport and PK-PD Experiments</b>	139
	1. Introduction	140
	2. Materials and methods	144
	3. Results	151
	4. Discussion	164
	5. References	168
<b>Chapter 5</b>	<b>The Intracerebral Rotenone Model of Parkinson's Disease in Rats - Altered Conversion of L-DOPA into DOPAC and HVA Without Changes in BBB Transport</b>	173
	1. Introduction	174
	2. Materials and methods	175
	3. Results	183
	4. Discussion	190
	5. References	195
<b>Section III</b>	<b>Conclusions and General Discussions</b>	199
<b>Chapter 6</b>	<b>Summary, Conclusions and Perspectives</b>	201
	<b>Nederlandse Samenvatting</b>	213
	<b>Nawoord</b>	225
	<b>Curriculum Vitae</b>	229
	<b>List of Publications</b>	231